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Antibodies (inhibitors) developed by hemophilia B patients against coagulation factor IX (FIX) are
challenging to eliminate because of anaphylaxis or nephrotic syndrome after continued infusion. To
address this urgent unmet medical need, FIX fused with a transmucosal carrier (CTB) was produced in a
commercial lettuce (Simpson Elite) cultivar using species speciﬁc chloroplast vectors regulated by
endogenous psbA sequences. CTB-FIX (~1 mg/g) in lyophilized cells was stable with proper folding, di-
sulﬁde bonds and pentamer assembly when stored ~2 years at ambient temperature. Feeding lettuce
cells to hemophilia B mice delivered CTB-FIX efﬁciently to the gut immune system, induced LAPþ reg-
ulatory T cells and suppressed inhibitor/IgE formation and anaphylaxis against FIX. Lyophilized cells
enabled 10-fold dose escalation studies and successful induction of oral tolerance was observed in all
tested doses. Induction of tolerance in such a broad dose range should enable oral delivery to patients of
different age groups and diverse genetic background. Using Fraunhofer cGMP hydroponic system,
~870 kg fresh or 43.5 kg dry weight can be harvested per 1000 ft2 per annum yielding 24,000e36,000
doses for 20-kg pediatric patients, enabling ﬁrst commercial development of an oral drug, addressing
prohibitively expensive puriﬁcation, cold storage/transportation and short shelf life of current protein
drugs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biopharmaceuticals produced in current systems are prohibi-
tively expensive and are not affordable for large majority of the
global population. The cost of protein drugs ($140 billion in 2013)iversity of Pennsylvania, 240
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Ltd. This is an open access article uexceeds GDP of >75% of countries around the globe, making them
unaffordable in these countries [1]. One third of global population
earning <$2 per day can't afford any protein drug. Although re-
combinant insulin is sold commercially for ﬁve decades, it is still
not affordable for a large majority of global population. This is
because of their production in prohibitively expensive fermenters,
puriﬁcation, cold storage/transportation, short shelf life and sterile
delivery methods.
Production of biopharmaceutical proteins in plants provides a
cost-effective solution. Oral delivery of protein drugs bio-
encapsulated in plant cells signiﬁcantly reduces downstream pro-
cessing costs by eliminating expensive puriﬁcation, cold storage/
transportation, and short shelf life [2e4]. Plant cells expressing
therapeutic proteins can be inexpensively processed by lyophili-
zation and stored at room temperature for several months or yearsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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be grown in the ﬁeld with appropriate biological containment of
foreign genes, such as maternal inheritance or male sterility and/or
harvest of vegetative tissues before ﬂowering [6].
Oral delivery of protein drugs has been elusive for decades
because of their degradation in the digestive system, inability to
cross the gut epithelium and delivery to target cells. However,
several recent studies have unequivocally shown that plant cell
wall protects expressed protein drugs from acids and enzymes in
the stomach via bio-encapsulation [2e4]. Human digestive en-
zymes are incapable of breaking down glycosidic bonds in car-
bohydrates that make up plant cell wall. However, when intact
plant cells containing protein drugs reach the gut, commensal
microbes digest plant cell wall and release protein drugs in the
gut lumen. Bacteria inhabiting the human gut have evolved to
utilize complex carbohydrates in plant cell wall and are capable
of utilizing almost all plant glycans [7,8]. Fusion of the (nontoxic)
Cholera toxin B subunit (CTB) to a reporter protein (GFP)
expressed in chloroplasts and bioencapsulated in plant cells was
orally delivered across the gut epithelium through GM1 re-
ceptors and furin cleavage site engineered between CTB-GFP
released GFP into circulation or different tissues [9]. Fusion of
CTB to therapeutic proteins facilitate their effective oral delivery
for induction of oral tolerance [10e13] or deliver functional
proteins to sera [5,14,15] or across blood brain or retinal barriers
[15,16].
Hemophilia is an X-linked bleeding disorder caused by mu-
tations in coagulation factor VIII (FVIII, hemophilia A) or factor IX
(FIX, hemophilia B). Hemophilia patients are currently treated by
replacement therapy with recombinant or plasma-derived factor
concentrate. However, 20e30% of patients with severe hemo-
philia A (as deﬁned by <1% coagulation activity) and ~5% of se-
vere hemophilia B patients develop inhibitory antibodies (or
“inhibitors”), which seriously complicate treatment and increase
morbidity and mortality of the disease [17e19]. Therefore, im-
mune tolerance induction to eliminate these inhibitors is
required to restore effectiveness of factor replacement therapy.
Current clinical protocols for reversal of the antibody response
via immune tolerance induction (ITI) require frequent high-dose
factor administration for prolonged periods (from months to
more than 1 year), and the costs are extremely high (often
exceeding one million dollars) [18]. Among hemophilia B pa-
tients, those with F9 gene deletions are at an elevated risk for
inhibitor formation. Often ITI protocols for FIX inhibitors cannot
be completed because of anaphylactic reactions or development
of nephrotic syndrome [20]. There are currently no prophylactic
ITI protocols to prevent inhibitor formation. Such a protocol
should ideally avoid immune suppressive drugs because in-
hibitors tend to form at a very young age (during the ﬁrst 50 days
of exposure) [18]. To address this unmet medical need, we are
developing an oral tolerance protocol using clotting factors
expressed in plant cells [11e13,21].
In this study, we created FIX-transplastomic plants in an edible
system ideal for oral delivery. Production of protein drugs in chlo-
roplasts offers several unique advantages including high-level
expression (up to 70% total leaf protein) [22], transgene contain-
ment from pollen transmission via maternal inheritance of trans-
genes and lack of gene silencing/position effect due to site speciﬁc
integration of the transgenes [23]. Although we suppressed inhib-
itor formation and anaphylaxis against human FIX in hemophilia B
mice using tobacco cells [11,13] further clinical development was
not feasible. We report here the ﬁrst successful development and
large scale production of CTB-FIX in a cGMP facility in an edible
crop plant (lettuce) and evaluation of therapeutic efﬁcacy in a wide
dose range and product stability.2. Materials and methods
2.1. Construction of lettuce chloroplast transformation vector
To construct the lettuce chloroplast CTB-FIX expression vector,
PCR was ﬁrst performed to amplify the CTB-FIX fusion gene with
the primer set NdeI-CTB-Fw (50 TTCATATGACACCTCAAAA-
TATTACTGATT 30, the underlined nucleotides represent the start
codon of CTB fusion tag) and XbaI-FIX-Rv (50 GATCTA-
GATTAAGTGAGCTTTG TTTTTTCCT 30, the underlined nucleotides
indicate the stop codon of FIX) from a template plasmid pLD CTB-
FFIX [11]. The CTB-FIX PCR products were cloned into pCR-Blunt
II-TOPO Vector (Life Technologies Co., Carlsbad, CA). After veriﬁ-
cation of nucleotide sequence, the NdeI-CTB-FIX-XbaI fragment
was subcloned into an NdeI-XbaI digested intermediate vector
pDVI-1 harboring a lettuce psbA promoter-50 UTR and lettuce psbA
30 UTR. The CTB-FIX expression cassette including the lettuce psbA
promoter-50 UTR/CTB-FIX/lettuce psbA 30 UTR was obtained by SalI-
NotI digestion and then cloned into SalI-NotI digested pLS-LF vector
[10] to create the CTB-FIX lettuce chloroplast expression vector
pLS-CTB-FIX (Fig. 1A).
2.2. Transformation and characterization of lettuce transplastomic
lines
Lettuce (Lactuca sativa) cv. Simpson Elite leaves were bom-
barded with the CTB-FIX expression vector and the chloroplast
transformants were selected on spectinomycin as previously
described [24]. In order to identify the site speciﬁc integration of
the CTB-FIX transgene into the chloroplast genome and to verify
the homoplasmic plants, PCR analysis and Southern blot assays
were performed according to previous reports from our laboratory
[24,25].
2.3. Lyophilization of the CTB-FIX transplastomic leaves
Frozen lettuce leaves expressing CTB-FIX fusion proteins were
freeze-dried in a lyophilizer (Genesis 35XL, SP Scientiﬁc, Stone Ridge,
NY) at40 C,30 C,20 C,15 C, 10 C,5 C and 25 C for a
total of 72 h under vacuum 400 mTorr. The lyophilized leaves
were ground in a coffee grinder (Hamilton Beach, Southern Pines,
NC) at maximum speed for 3 times (each time, pulse on 6 s and off
90 s). The ﬁne powder or lyophilized leaves were stored in moisture
free containers at room temperature with silica gels up to 2 years.
2.4. Analysis of CTB-FIX expression in transplastomic lettuce leaves
Immunoblot analysis and quantitation of the CTB-FIX fusion
protein were carried out by previously reported protocols [5,24]. In
order to analyze the pentameric structure of CTB-FIX fusion protein
expressed in the transformed lettuce chloroplasts, GM1-
ganglioside receptor binding ELISA and non-reducing gel-western
blot assays were performed as reported earlier [5].
2.5. Hemophilia B mouse experiments
Hemophilia B mice with F9 gene deletion on C3H/HeJ back-
ground (C3H/HeJ F9/) were bred as previously published
[11,26,27]. Male mice approximately 2 months of age were used at
the onset of experiments and housed under special pathogen-free
conditions at the University of Florida under institutionally
approved protocols. Lyophilized plant cells were rehydrated in
sterile PBS to a ﬁnal volume of 200 ml per gavage dose (containing
1.5e15 mg of CTB-FIX antigen) and brieﬂy vortexed for 3-4 seconds.
Oral delivery was performed twice per week for 8 weeks by gavage
Fig. 1. CTB-FIX lettuce chloroplast expression vector and evaluation of site-speciﬁc integration into the lettuce chloroplast genome. (A) Schematic diagram of CTB-FIX lettuce
expression vector pLS-CTB-FIX. Homologous chloroplast genome ﬂanking sequences include 16S (16S rRNA), isoleucine tRNA (trnI), alanine tRNA (trnA) genes. A glycineeproli-
neeglycineeproline hinge and furin cleavage site (RRKR) are inserted between CTB and the FIX sequence. The CTB-FIX expression is regulated by the lettuce psbA promoter-50 UTR
(PpsbA) and 30 UTR (TpsbA). The selection marker gene aadA (encoding aminoglycoside 30-adenylyltransferase gene to confer spectinomycin resistance) is driven by a ribosomal
RNA operon promoter (Prrn) with GGAG ribosome binding site. (B) PCR analysis of the CTB-FIX transplastomic lines. The primer annealing sites (16S-Fw/3M, 5P/2M and CTB-Fw/FIX-
Rv1) for PCR analysis of control and transplastomic lines are shown in Fig. 1A. L1, L2 and L3 represent three independent transplastomic lines. (C) Evaluation of homoplasmy in CTB-
FIX-transplastomic lines. Total lettuce DNA was digested with HindIII and probed with 32P-labeled 1.12 kb trnI/trnA ﬂanking region fragment. Untransformed line generates a 9.1 kb
hybridizing fragment while transplastomic lines generate 12.6 kb fragment due to site speciﬁc integration of the transgene cassette.
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ment therapy, mice were administrated 1 IU hFIX (Beneﬁx, Pﬁzer,
New York, NY) into the tail vein once per week for 8 weeks. Blood
was collected by tail bleed into citrate buffer. To prevent fatal
anaphylaxis in control animals (that did not receive oral tolerance),
anti-histamine and anti-platelet activating factor (anti-PAF) were
administered starting at the 4th injection [11,13]. Antibody for-
mation against FIX in murine plasma was measured by Bethesda
assay (using a ﬁbrometer from Stago, Pasippany, NJ) and by
immunoglobulin-speciﬁc ELISA as published [11,13]. Frozen tissue
sections from small intestine were prepared for immunohisto-
chemistry and stained for FIX and CD11c antigens as previously
documented [13].
2.6. Scaled-up hydroponic cGMP production of CTB-FIX biomass
A hydroponic system amenable to development into a cGMP
pilot-scale production system was assembled. The hydroponicsystem consisted of two wire shelving units. In each rack there
were four growing areas that were illuminated with three
sealed lighting ﬁxtures containing 2-T8 ﬂuorescent bulbs. Two
growth trays containing rockwool horticultural substrate (Gro-
dan, The Netherlands) were placed on each shelf. The nutrient
comprised a 20-10-20 ratio of nitrogen, phosphorus and
potassium.
CTB-FIX seeds were placed on the rockwool surface at
2 inch  2 inch spacing. Plants received an average of
70e90 mmol m2 s1 of light on an 18 h photoperiod. The tem-
perature and humidity in the growth room ranged from 23 to 26 C
and 20e60%, respectively. This hydroponic plant growth system is a
small-scale arrangement that can be scaled to cGMP pilot scale
production [28]. For a comparison of germination and biomass
accumulation rates, CTB-FIX plants were grown alongside the
commercial cultivar Simpson Elite.
Fig. 2. Evaluation of CTB-FIX expression in the lettuce transplastomic lines. (A)
Western blot analysis of CTB-FIX in three independent lines and WT controls. Plant
total leaf proteins (5 mg/lane) were loaded from WT and CTB-FIX plants. CTB, 3 ng per
lane. L1, L2, L3: 3 independent lettuce transplastomic lines. WT, untransformed wild
type plant. Antibody titers: rabbit anti-CTB polyclonal antibody 1:10,000; goat anti-FIX
polyclonal antibody 1:2000. (B) Quantitation of CTB-FIX expression at different
developmental stages. Total leaf protein (1.5 mg per lane) was loaded from young,
mature and old leaves (2.5-months-old plants grown in the greenhouse). Probe: anti-
CTB rabbit polyclonal antibody (titer 1:10,000). Right bar graph shows CTB-FIX con-
centrations of young, mature and old leaves. Data shown are means ± SD of two
replicates from leaves collected from two independent lines. (C) Non-reducing gel
western blot analysis. Probe, anti-CTB rabbit polyclonal antibody (titer 1:10,000).
Protein concentration loaded: CTB, 3 ng per lane; CTB-FIX (L1, L2 and L3) and WT leaf
extracts, 5 mg (TLP) per lane.
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3.1. Lettuce CTB-FIX chloroplast expression vector
Our goal is to create an edible leafy crop plant (lettuce) capable
of producing adequate levels of FIX antigen in chloroplasts to
facilitate clinical translational studies. In order to enhance trans-
formation efﬁciency, lettuce species speciﬁc chloroplast vector was
constructed using endogenous full length (~2 kb/ﬂank) ﬂanking
sequences. Likewise, we used lettuce psbA promoter, 50UTR and 30
UTR to enhance transgene expression. These concepts formed the
basis for design and construction of pLS-CTB-FIX expression vector
(Fig. 1A). For expression of FIX antigen, an N-termial truncated
version (47th e 461st amino acids) of human FIX cDNA
(FR846240.1) excluding the signal peptide (1st e 28th) and pro-
peptide (29th e 46th) was used to generate the CTB-FIX expression
vector. The vector contained the spectinomycin selection marker
gene aadA which could be removed by direct repeats (see discus-
sion section). In addition, a glycineeprolineeglycineeproline
(GPGP) hinge to prevent steric hindrance was created between CTB
and FIX fusion elements. A furin cleavage site (RRKR) was also
included in this CTB-FIX expression vector [11]. While this
construct lacks the FIX propeptide (which is required for g-
carboxylation) and thus cannot produce functional FIX, the entire
amino acid sequence of mature FIX is included, covering all po-
tential CD4þ T cell epitopes for tolerance induction.
3.2. Characterization of CTB-FIX transplastomic lettuce lines
CTB-FIX transplastomic lettuce lines were created by biolistic
particle bombardment of lettuce leaves from a commercial cultivar
(Simpson Elite) with the expression vector pLS-CTB-FIX. PCR results
showed the correct sizes of amplicons, 2.77 kbwith primer set 16S-
Fw/3M, 3.60 kb with 5P/2M and 1.34 kb with CTB-Fw/FIX-Rv1
(Fig. 1A and B). The site-speciﬁc integration of the CTB-FIX gene
into the chloroplast genome was further conﬁrmed by Southern
blot analysis probed with the lettuce trnI and trnA ﬂanking
sequence. All three independent transplastomic lines showed
distinct hybridizing fragments in Southern blots with the expected
size of 12.6 kb but not the 9.1 kb fragment from untransformedwild
type plants (Fig. 1A, C), conﬁrming that all three CTB-FIX trans-
plastomic lines were homoplasmic (in which all chloroplast
genome have been transformed with insertion of the transgene
cassette).
3.3. Folding, stability and CTB-FIX pentamer assembly in lyophilized
lettuce leaves
Total leaf proteins were extracted with a fully denatured and
reducing buffer to analyze CTB-FIX protein. As shown in Fig. 2A, the
monomer CTB-FIX fusion protein with the correct molecular mass
of 59.2 kDa was detected with anti-CTB or FIX antibody. All trans-
plastomic lettuce lines expressing CTB-FIX were fertile and set
seeds. In T1 plants, CTB-FIX expression levels of the young, mature
and old leaves were 0.63%, 0.58% and 0.48% of total leaf protein
(TLP) respectively (Fig. 2B). The CTB-FIX concentration of the frozen
mature leaves was up to 58.38 mg per g of fresh leaves. CTB-FIX
pentamer (296.0 kDa) properly assembled in the transgenic let-
tuce chloroplasts (Fig. 2C). Absence of any cleaved products afﬁrms
stability of assembled pentamers in plant extracts.
Frozen CTB-FIX lettuce mature leaves were freeze-dried using a
lyophilizer as described in the methods section. Fig. 3A shows a
direct comparison of protein concentrations in lyophilized and
frozen leaf samples by weight (5e200 mg, 1e40 dilution) and an
increase of 18e21 fold CTB-FIX protein concentrationwas observedafter lyophilization. The intact monomer band of CTB-FIX fusion
protein was observed without any detectable degradation of CTB-
FIX in all tested lyophilized samples after storage for 2, 6, 12 and
24 months, at ambient temperature (Fig. 3B), conﬁrming that CTB-
FIX protein is stable in the freeze-dried lettuce leaves up to 2 years.
The stability of the CTB-FIX fusion protein concentrations was
similar in all tested samples when normalized for total protein
concentration. CTB-FIX concentrations were 0.59% TLP (equivalent
to1478.54 mg/gDW) after 2 month storage, 0.56% TLP (equivalent to
1155.60 mg/gDW) after 6 month storage, 0.54% TLP (equivalent to
846.43 mg/gDW) after 12 month storage and 0.57% TLP (equivalent
to 927.02 mg/gDW) after 24 month storage. The results of Paired
student's t-test indicated absence of any signiﬁcant difference in %
TLP of CTB-FIX among lyophilized samples stored for different
Fig. 3. Evaluation of CTB-FIX concentration and stability after long term storage of lyophilized lettuce leaves. (A) Comparison of CTB-FIX protein concentration of lyophilized CTB-
FIX lettuce leaves with the frozen leaf samples. 1X̶ 40X indicate fold of dilution. One fold (1X) equals 200 mg (in weight) of leaf ground powder. (B) Evaluation of CTB-FIX protein
stability in lyophilized lettuce leaves during long term storage at ambient temperature. Two independent blots by loading either 2.0 mg or 1.5 mg of TLP per lane are shown. Probe:
anti-CTB rabbit polyclonal antibody (titer, 1:10,000). Right bar graph shows the CTB-FIX concentrations of the 4 batches of lyophilized leaves after different periods of storage (2, 6,
12 and 24 months). Data shown are means ± SD of three independent experiments. (C) GM1 binding assay. CTB: CTB standard protein (5 ng). Lyo-2M, Lyo-6M, Lyo-12M, Lyo-24M:
Total soluble protein (TSP, 100 mg) from the lyophilized CTB-FIX expressing leaves after storage for 2, 6, 12 and 24 months at room temperature. Lyo-WT, protein extract (100 mg, TSP)
from lyophilized and untransformed wild type leaves. BSA, bovine serum albumin (100 mg). Data shown are means ± SD of two independent experiments. (D) Comparative analysis
of CTB-FIX protein concentrations in lyophilized lettuce leaves from Fraunhofer (Fraun, hydroponic system) with leaf samples collected from the Daniell lab greenhouse at Uni-
versity of Pennsylvania (UPenn, potted soils). 1.5 mg TLP per lane was loaded. Probe: anti-CTB rabbit polyclonal antibody (titer, 1:10,000). Left panel represents results of the 1st leaf
harvest (plant ages: Fraunhofer, 32-days-old; UPenn, 66-days-old) and the right panel shows results of the 2nd leaf harvest (plant ages: Fraunhofer, 51-days-old; UPenn, 86-days-
old).
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A plasma membrane receptor (GM1-ganglioside) binds CTB
in vivo, and pentamer formation of CTB is required for binding to
GM1 receptor [29,30]. To further test if the pentameric structure
with disulﬁde bonds was maintained in lyophilized lettuce leaves,
GM1-ganglioside receptor binding ELISA was carried out using the
lyophilized leaves after long term storage at ambient temperature.
CTB-FIX fusion protein extracts from all tested samples showed
strong binding afﬁnity to GM1 (Fig. 3C), demonstrating the pres-
ence and functional stability of the CTB-FIX pentamers in lyophi-
lized leaves even after long term storage (~2 years).
3.4. Scale up of biomass and CTB-FIX dose evaluation in capsules
CTB-FIX lettuce plants were transplanted into potted soils in the
greenhouse to set seeds. For production of CTB-FIX in a scalablehydroponic system, CTB-FIX seeds were germinated on rockwool or
in Petri dishes on ﬁlter paper with the nutrient solution. The
germination rate of CTB-FIX lettuce seeds on rockwool was 93%
when compared to 100% in Petri dishes on ﬁlter paper with the
nutrient solution. After 32 days of growth, the WT Simpson Elite
plants produced more leaf biomass (236.72 g per ﬂat) than CTB-FIX
plants (144.89 g per ﬂat). This difference in biomass accumulation
was anticipated based on the additional burden of constitutively
synthesizing a foreign human protein (Fig. 4A). The CTB-FIX protein
concentration in the lyophilized lettuce leaves collected from the
hydroponic system contained 0.38% TLP (equivalent to 1007.55 mg/
gDW) which is lower than 0.56% TLP (equivalent to 1459.59 mg/
gDW) in lyophilized CTB-FIX lettuce leaves harvested from the
Daniell lab greenhouse at the University of Pennsylvania (Fig. 3D).
Two batches of leaves from different harvests at Fraunhofer (32, 51
days old) and UPenn greenhouse (66, 86 days old) samples were
Fig. 4. Industrial production of FIX bioencapsulated in lettuce cells. (A) Biomass production of CTB-FIX lettuce. CTB-FIX lettuce plants were grown in potted soils in the Daniell lab
greenhouse at the University of Pennsylvania or in Fraunhofer cGMP hydroponic system (Upper 2 panels). The lower 2 panels show the growth status of CTB-FIX lettuce (cv.
Simpson Elite, 24 days old) and wild type (WT) lettuce (cv. Simpson Elite, 24 days old). (B) Capsule preparation. A large scale production of FIX-expressing lettuce was established in
Fraunhofer USA (Newark, DE). After harvesting and lyophilization (Lyophilizer: Genesis 35XL, SP Scientiﬁc, Stone Ridge, NY) of the fresh leaves, the freeze-dried FIX leaves were
powdered and prepared as capsules.
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the hydroponic system, ~870 kg of fresh FIX-lettuce leaves (~43.5 kg
dry weight) can be harvested per thousand ft2 of growth room
annually. Up to 43.5 g of FIX can be produced from 43.5 kg of dry
FIX-lettuce leaves, yielding 24,000e36,000 doses for 20-kg pedi-
atric patients (based on the lowest or highest effective dose for
induction of oral tolerance). After lyophilization, the freeze-dried
FIX lettuce leaves were ground into ﬁne powder and used to pre-
pare FIX-lettuce capsules (Fig. 4B).
3.5. Oral delivery of CTB-FIX lettuce cells suppressed inhibitor
formation against FIX in hemophilia B mice
First, we wanted to conﬁrm that oral administration of CTB-FIX
bioencapsulated in lettuce cells results in delivery of the FIX anti-
gen to the gut immune system. Lyophilized lettuce (after storage for
eight months at ambient temperature) plant cells (containing 10 mg
CTB-FIX) were resuspended in sterile PBS and delivered to hemo-
philia B mice by oral gavage. Five hours later, the small intestine
was removed. Immunohistochemical staining of cryosectionsconﬁrmed delivery of FIX antigen to the gut epithelium and to
Peyer's patches (Fig. 5A), with efﬁciency similar to our previous
observations on FVIII and FIX delivery of tobacco cells [11e13].
Uptake of FIX antigen to dendritic cells (DC) was demonstrated by
co-localization with CD11cþ cells (DCs, Fig. 5BeD). Systemic de-
livery of FIX antigen was observed 2 and 5 h after gavage of lettuce
cells at levels similar to those achieved from feeding of identical
antigen doses contained in tobacco cells (Fig. 5E).
Next, hemophilia B mice received oral gavages of the lettuce
material twice per week for 2 months (Fig. 6A). A ten-fold dose
escalation (1.5 mg or 15 mg) of CTB-FIX (in 1.9 or 19 mg lyophilized
lettuce cells) was investigated. Control mice received WT un-
transformed lettuce. During the second month of this regimen, all
mice (n ¼ 11 for control and low dose, n ¼ 7 for high dose) were
additionally i.v. injected with recombinant FIX (1 IU) once per
week. This replacement therapy was continued for 1 month after
oral gavages had been stopped (Fig. 6A). Blood samples were
collected 1 week after the last FIX injection. FIX inhibitor titer was
robustly suppressed by oral delivery of CTB-FIX expressing lettuce
cells for both doses (Fig. 6B). Average titers were 15efold lower, and
Fig. 5. FIX antigen delivery to the small intestine of hemophilia B mice. (A) FIX (red)
delivered to epithelium of intestinal villi and to Peyer's patches (PP). DAPI was used to
stain nuclei blue. (B) Examples of co-localization (arrows) of FIX antigen and CD11cþ
cells, indicating antigen delivery to DC in PP. (C) Examples of co-localization (arrows)
of FIX antigen and CD11cþ cells, indicating antigen delivery to DC in villi. Mice had
received oral gavages of CTB-FIX expressing lettuce (but no i.v. FIX). (D) No FIX stain
was observed in mice that received oral gavage of WT lettuce (shown), or in intestinal
sections of CTB-FIX fed mice when the primary antibody against FIX was omitted
during staining (not shown). Original magniﬁcation for all panels: 200. (E) Systemic
human FIX levels as measured by ELISA 2 and 5 h after oral gavage of 10 mg CTB-FIX
bioencapsulated in lettuce or tobacco cells. Data shown are average ± SD (n ¼ 3/
group). Differences between lettuce and tobacco were not signiﬁcant (“ns”).
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group had very low (<2 BU) to undetectable inhibitor titers. In
contrast, control mice formed high-titer inhibitors (11/11 >5BU,
with 9/11 > 10 BU). IgG1 was the dominant subclass of IgG pro-
duced against FIX. Average IgG1 titers were suppressed by 3efold,
and e in contrast to control mice e no titers >20,000 ng/ml were
measured (Fig. 6C). Because repeated i.v. delivery of FIX causes not
only inhibitor formation but also fatal anaphylaxis in the C3H/HeJ
F9/ strain, control mice were additionally treated with drugs that
prevent anaphylactic reactions. Mice that had received oral toler-
ance using high- or low-dose CTB-FIX in lettuce, despite not being
treated with these drugs, did not develop anaphylaxis, consistent
with suppression of IgE formation (Fig. 6D). At the end of these
experiments, different organs were analyzed for induction of LAPþ
Treg by ﬂow cytometry. A signiﬁcant increase in the frequency of
LAPþCD25CD4þ Treg was found in the spleen, mesenteric lymph
nodes, and Peyer's patches (but not in control lymph node) of FIX
fed mice (Fig. 6E).4. Discussion
Even though one protein drug made in carrot cells has been
approved by FDA [1], this did not eliminate prohibitively expensive
fermentation, puriﬁcation, cold storage or transportation costs.
Therefore, this reports the ﬁrst clinical advancement of a protein
drug made in edible plant cells for oral drug delivery. Successful
generation of transplastomic lettuce plants at an industrial scale is a
major step towards development of a clinical protocol for inducing
oral tolerance in hemophilia patients.
In addition, fusion to CTB ensures highly efﬁcient targeting of
the gut immune system for oral tolerance induction [10e13]. CTB
assembles into a stable pentameric ring consisting of ﬁve identical
11.5-kDa polypeptide monomers. CTB pentamers bind to GM1
ganglioside receptors on the membranes of gut epithelial cells and
on DCs [10e13,31,32]. Role of CTB in induction of oral tolerance has
been reported by several investigators [10e13,33,34]. Clinical data
to support the safety of CTB administration to humans [35] has
already been approved for human use a decade ago and is used by
hundreds of millions of people around the globe [36]. The suc-
cessful induction of oral tolerance by CTB-autoantigen conjugates
in experimental systems has been also proven to be safe in clinical
trials [37]. Extensive pre-clinical evaluation leading to these clinical
studies have shown that recombinant CTB or CTB fusions do not
cause histopathology in the small intestine, nor do they increase
vascular permeability [38].
CTB may enhance tolerance induction also by induction of
indoleamine 2, 3-dioxygenase (which is known to aid in Treg in-
duction) in DC [39]. Upon uptake by epithelial cells, FIX is cleaved
off at the engineered Furin cleavage site and in part systemically
delivered [11]. Furthermore, FIX antigen is delivered to several
subsets of antigen presenting cells (APCs) in the GALT. These
include F4/80þ cells in the duodenum and CD11cþ DC (including
tolerogenic CD103þ DC) in the lamina propria and in Peyer's
patches (PP) throughout the small intestine [13]. Direct uptake by
DC that sample the gut lumen and transport to DC in PP by M cells
likely also contribute to antigen uptake resulting in an increase in
several subsets of DCs and CD4þ T cells. IL-10 dependent and
antigen-speciﬁc immune regulatory response ultimately sup-
presses systemic antibody formation via induction of
CD4þCD25þFoxP3þ Treg and CD4þCD25FoxP3LAPþ Treg [13].
LAPþ Treg overexpress TGF-b (resulting in detectable latency
associated peptide (LAP) on the cell surface, suppress via a TGF-b
dependent mechanism, and may be more immune suppressive
than FoxP3þ Treg [40,41]. Upon systemic challenge with FVIII or
FIX, our oral tolerance protocol increases the overall frequency of
LAPþ Treg, and these induced Treg up-regulate IL-10 and TGF-b
expression in response to antigen [12,13].
Use of freeze-dried plant cells facilitates pharmaceutical pro-
duction and formulation. In this study, we observed that CTB-FIX
fusion protein in lyophilized lettuce can be stored at room tem-
perature up to 2 years without any detectable degradation of this
protein. We used material that had been stored for 8 months to
tolerize the hemophilic mice over a wide dose range. The long-
shelf-life of freeze-dried CTB-FIX lettuce leaves eliminates the
need for expensive protein puriﬁcation, cold storage, cold trans-
portation and addresses a major challenge in production and de-
livery of current protein drugs. Therefore, lettuce-made FIX would
be ideal for large scale and cost effective production of this bio-
pharmaceutical for translational studies of hemophilia B.
In the present study, no signiﬁcant difference for oral tolerance
inductionwas observed between low-dose- (1.5 mg of CTB-FIX) and
high-dose-treated (15 mg of CTB-FIX) hemophilia B mice, which
may be due to highly efﬁcient CTB-mediated delivery of FIX anti-
gen. This will be a major advantage in further clinical advancement
Fig. 6. Suppression of inhibitor and IgE formation against FIX in hemophilia B mice. (A) Mice were given two gavages weekly (of different CTB-FIX doses) of lettuce cells and were
challenged with i.v. injections of FIX. (B) Anti-FIX titers 1 week after the last i.v. injection of FIX are graphed as inhibitor titers in BU/ml. (C) IgG1, 2a, and 2b anti-FIX titers. (D) IgE
anti-FIX titers. (E) Frequencies of LAPþCD25CD4þ Treg in the spleen, mesenteric lymph nodes, Peyer's patches, and control (inguinal) lymph nodes of FIX fed and control mice. Flow
plots on the left show individual representative examples. Graph to the right shows results for individual mice (n ¼ 5/group) as well as averages ±SD.
J. Su et al. / Biomaterials 70 (2015) 84e93 91to overcome potential differences among patients in efﬁciency of
oral delivery of protein drugs bioencapsulated in plant cells. In the
unlikely event of requiring lyophilized materials with higher dose
(which could be simply achieved by taking more capsules), codon
optimized genes could be used instead of native human genes. An
additional improvement needed may be the removal of selectable
marker gene from transformed chloroplast genomes. Several
methods are readily available for removal of the selection marker
genes [42,43]. Precise excision of the selectable marker gene (aadA)
was also accomplished recently from the integration site (trnA/trnI)
used in this study with Bxb1 recombinase and attP/attB recognition
sites [44].
The demonstration of growing CTB-FIX and WT lettuce (cv.
Simpson Elite) plants in a controlled environment hydroponic
system illustrates that transformed plants performed well using
scalable production methods that are translatable to cGMP (cur-
rent Good Manufacturing Practices). There was no need to
germinate seeds in the presence of antibiotic. The indoor hydro-
ponic system does not require use of pesticides and herbicides.
This system can also avoid soil borne diseases. The fast growth
rate is another unique advantage of the hydroponic system and
one-month-old FIX-lettuce leaves were ready for the ﬁrst harvest.This opens a path towards human clinical evaluation of CTB-FIX, as
well as other similarly expressed proteins. For example, existing
plant-based biopharmaceutical production facilities operated un-
der the FDA's GMP guidelines can potentially be modiﬁed to
accommodate lettuce biomass production [28]. Under current
growth condition, the CTB-FIX concentration in the lettuce leaves
harvested from the hydroponic system was not as high as that
from UPenn Daniell lab greenhouse (1 mg/g vs 1.5 mg CTB-FIX/g
DW). This difference may be mainly due to different light source
and 3-fold lower intensity (sunlight ~280 mmol m2 s1 vs hy-
droponic system ~90 mmol m2 s1) because of the light-regulated
psbA promoter-50 UTR determining expression level of CTB-FIX
protein.
Mechanistic studies to understand molecular basis of tolerance
conferred by different blood clotting factors expressed in plant cells
and efﬁcacy of this system to not only induce tolerance but also
accomplish reversal [11e13] augurs well for further clinical ad-
vances. In this study for oral tolerance induction, the propeptide
sequence of FIX was not included in the CTB-FIX fusion protein
expressed in lettuce chloroplasts. It has been demonstrated that
this propeptide is required for gamma-carboxylation of the Gla
domain of the mature protein to produce functional FIX [45].
J. Su et al. / Biomaterials 70 (2015) 84e9392Therefore, the lettuce chloroplast-expressed FIX from this study
does not have blood clotting activity. Future studies will explore
delivery of functional clotting factors. Most importantly, elimina-
tion of prohibitively expensive fermentation, puriﬁcation, cold
storage/transportation, short shelf life of current protein drugs
makes this novel approach highly efﬁcient, cost-effective and
environmentally friendly for large scale production of therapeutic
proteins in plants, a major milestone in advancing this ﬁeld.
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